Chronic obstructive pulmonary disease (COPD) is regarded as one of the leading causes of
morbidity and mortality across the world, yet its proper diagnosis remains a challenge …

Background Three classes of inhaler medications are used to manage chronic obstructive
pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic …

Background Despite the availability of national and international guidelines, evidence
suggests that chronic obstructive pulmonary disease (COPD) treatment is not always …

Аннотация В настоящее время хроническая обструктивная болезнь легких (ХОБЛ)
является глобальной проблемой и одной из ведущих причин смерти в мире. Терапия …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …

Currently, chronic obstructive pulmonary disease (COPD) is a global health issue and one of
the leading causes of death in the world. COPD therapy includes pharmacological and non …

Резюме Терапия больных хронической обструктивной болезнью легких (ХОБЛ)–одна
из наиболее важных проблем внутренней медицины вследствие высокой …

Abstract The Finnish Medical Society Duodecim initiated and managed the update of the
Finnish national guideline for chronic obstructive pulmonary disease (COPD). The Finnish …

Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma, but their role in
chronic obstructive pulmonary disease (COPD) is debated. Recent randomised controlled …

Background Blood eosinophil count has been proposed as a predictor of response to
inhaled corticosteroid (ICS) in the prevention of acute exacerbations of COPD. An optimal …